【Mumbai】Indian drug-makers wanting to make AIDS drug atazanavir will now be able to do so, following a licensing agreement signed by multinational pharma firm Bristol-Myers Squibb (BMS) and UN-backed Medicines Patent Pool (MPP). Atazanavir, marketed by BMS under the Reyataz brand, is used in the second-line treatment of HIV/AIDS.
The agreement, announced on Thursday, will allow manufacturers worldwide to produce more affordable versions of atazanavir, and to combine atazanavir with other medicines, to make treatment easier and more accessible in developing countries, said Greg Perry, Executive Director of MPP. Generic drug-makers, many of which are in India, will be able to access the technology to make the drug, and export it to 110 countries.
The scope of the agreement covers over 88 per cent of the HIV/AIDS affected people in developing countries, said MPP.
【News source】
Generic possibilities from Bristol-Myers AIDS drug pact
Your Comments
Special sale for Ad Space
Free download of "The Origin of Christianity"
Readers' Voice
Trend
SEAnews World Circulation